Filter By Category
Archives
Share on -
ADEBRELIMAB
Generic Name: ADEBRELIMAB
ABSTRACT -
Adebrelimab is a humanized IgG4 monoclonal antibody targeting programmed death-ligand 1 (PD-L1). By blocking the PD-1/PD-L1 immune checkpoint interaction, it may restore antitumor T-cell activity. It has been approved in China for first-line treatment of extensive-stage small cell lung cancer in combination with chemotherapy, and it continues to be studied in other solid tumors under oncology supervision.
DOSAGE -
Adebrelimab should be used only under specialist oncology supervision according to the locally approved product information or clinical-trial protocol.
- In extensive-stage small cell lung cancer studies, it has been administered by intravenous infusion in combination with platinum-etoposide chemotherapy, followed by maintenance immunotherapy according to protocol.
- Dose, infusion duration, treatment cycle, premedication, and duration depend on the approved label or trial protocol.
- Treatment may require delay or discontinuation for immune-mediated toxicity, severe infusion reaction, or disease progression.
- Patients should not self-medicate or combine it with other immunotherapies unless prescribed by the oncologist.
SIDE EFFECTS–
Reported or potential side effects may include:
- Fatigue
- Decreased appetite
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Rash or itching
- Cough
- Pneumonitis
- Hepatitis or liver enzyme elevation
- Colitis
- Endocrine disorders such as thyroid dysfunction, adrenal insufficiency, or diabetes
- Nephritis
- Infusion-related reactions
- Anemia, neutropenia, or thrombocytopenia when combined with chemotherapy
- Infection
- Allergic or hypersensitivity reactions
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Skin rash
- Itching
- Hives
- Swelling of face, lips, tongue, or throat
- Difficulty breathing
- Wheezing
- Severe dizziness
- Rapid heartbeat
- Chest tightness
- Anaphylaxis
- Severe hypersensitivity reactions
DRUG INTERACTIONS–
The full drug-interaction profile has not been completely established. Use caution with:
- Systemic corticosteroids or immunosuppressants used before or during immunotherapy
- Other immune checkpoint inhibitors or immune-stimulating anticancer medicines
- Chemotherapy combinations with overlapping marrow, renal, hepatic, or gastrointestinal toxicity
- Live vaccines during immune-modulating cancer therapy
- Other investigational medicines or therapies used in the same protocol
- Medicines that increase the risk of overlapping organ toxicity
- Immunosuppressive, anticancer, antiviral, cardiovascular, or neurologic medicines when clinically relevant
- Herbal products and supplements with uncertain pharmacologic effects
PREAUTIONS–
- Assess autoimmune disease history, transplant history, baseline lung disease, liver function, endocrine status, and infection status before treatment.
- Monitor for immune-mediated pneumonitis, colitis, hepatitis, endocrinopathy, nephritis, skin reactions, and neurologic toxicity.
- Use only in settings where qualified healthcare professionals can assess eligibility, monitor response, and manage adverse reactions.
- Review baseline medical history, organ function, concomitant medicines, pregnancy status, and allergy history before use.
- Monitor clinical symptoms and laboratory values as directed by the clinical protocol or treating specialist.
- Use caution in patients with severe hepatic, renal, cardiovascular, infectious, immune, or neurologic disease unless specifically allowed by protocol.
- Use during pregnancy or breastfeeding only if the potential benefit justifies the potential risk and as directed by a physician.
- Safety and effectiveness in pediatric patients may not be established unless specifically studied.
WARNINGS –
- Immune-mediated adverse reactions can be serious or fatal and may involve any organ system.
- New cough, shortness of breath, diarrhea, abdominal pain, jaundice, severe rash, confusion, weakness, or endocrine symptoms require prompt evaluation.
- This medicine is investigational or has limited publicly established clinical-use information; safety, efficacy, optimal dose, and routine clinical role may not be fully established.
- It should not be used for self-medication or substituted for an approved therapy unless directed by a qualified specialist or clinical-trial investigator.
- Treatment should be discontinued and urgent medical care sought if severe allergic reaction, severe adverse reaction, or clinical deterioration is suspected.
- Use only under medical supervision in an appropriate specialist or clinical-trial setting.
- Keep out of reach of children.
- In case of overdose or severe adverse reaction, seek immediate emergency medical attention.
Share on -
. Developed by